Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (575)	10/18/2006 2:17:45 AM
From: tnsaf	Read Replies (1) \| Respond to of 802

I don't know if PGS is any good, but following the discussion of Telik's Assist trials on his biotech blog Biotech+ (http://biotechplus.blogspot.com) is the following "On other matters, we're going to make a couple of additions: [...] 2) We're also going short 2800 shares of INGN at Friday's (the 13th!) closing price of $4.4701, a total "cost" of $12516.28. This company is simply not being straightforward with the market, so we're going to take advantage. Watch for their Advexin registration strategy to fall flat on its face. I'm looking to cover this at around $3.50 per share, barring unforeseen developments. The general strategy with short positions will be to hold long term even if it goes against us in the short term. Since we're mostly concerned with fundamentals, and since INGN's fundamentals suck, patience should provide good returns."